Structure of key cancer drug target identifiedOctober 26, 2005Researchers from Monash's Department of Biochemistry and Molecular Biology have determined the structure of the protein JAK2 kinase, a discovery with huge implications for the design and development of new cancer drugs. NHMRC Industry Research Fellow Dr Isabelle Lucet, from Monash's Protein Crystallography Unit headed by Dr Jamie Rossjohn, was part of the team that determined the structure. JAK2 kinase was the driving force for many cancers and cardiovascular disorders, she said. The research, partly funded by a $1.2 million Australian Research Council Linkage Grant, was a joint project between drug development company Cytopia Limited and the Protein Crystallography Unit. The JAK kinases, which were first discovered by Cytopia's chief scientific officer Dr Andrew Wilks, are a well-validated drug target. Dr Lucet said the discovery of JAK2 kinase's structure had allowed an internationally competitive structure-based drug design on JAK kinase inhibitors to begin. "This will help the development of drugs for cancer and other disorders by assisting with the design of specific molecules." She said the high expertise of the Monash research team, combined with the drug discovery capability of Cytopia, would undoubtedly enable more selective drug targets to be developed against diseases where the JAK kinases play a pivotal role. Dr Lucet said the new discovery would allow the rapid growth of a portfolio of phase I therapeutics. Research Australia |
|||||||||||||||||||||
| Related Cancer Drug Current Events and Cancer Drug News Articles Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Duke develops nano-scale drug delivery for chemotherapy Going smaller could bring better results, especially when it comes to cancer-fighting drugs. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Sensor biochips could aid in cancer diagnosis and treatment It is very difficult to predict whether a cancer drug will help an individual patient: only around one third of drugs will work directly in a given patient. Metals could forge new cancer drug Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds. OU Part of International Study on Genetic Impact of Radiation Researchers at the University of Oklahoma Health Sciences Center are helping to lead a massive international study on the possible genetic effects of radiation and cancer drug exposures on future generations. New Chemo Cocktail Blocks Breast Cancer Like a Fence Think of a protective fence that blocks the neighbor's dog from charging into your backyard. The body, too, has fences -- physical and biochemical barriers that keep cells in their place. Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease. More Cancer Drug Current Events and Cancer Drug News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||